CEACAM5 and neoplasm: The difference between CEACAM5-TCB vs. cibisatamab treatment at a dose of 2.5 mg/kg was not significant in that study (p = 0.8) and both showed very strong anti-tumour effect with a lower mean AUCE of 16,042 mm3/h in case of CEACAM5-TCB.